Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

Influenza virus is a pathogen that causes morbidity and mortality worldwide. Whereas vaccination is important for prevention of disease, given its limitations, antiviral therapy is at the forefront of treatment and also plays a role in prevention. Currently, two classes of antiviral medications, the adamantanes and the neuraminidase inhibitors, are approved for treatment. Given the resistance patterns of circulating influenza, adamantanes are not recommended. Within the US, two neuraminidase inhibitors are currently approved for both treatment and prevention, while worldwide there are four available. In this review, we will briefly discuss the epidemiology and pathology of influenza and then discuss neuraminidase inhibitors: their mechanism of action, resistance, development, and future applications.

[1]  Yufei Wang,et al.  High severity and fatality of human infections with avian influenza A(H7N9) infection in China. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Dayan Wang,et al.  Monitoring Avian Influenza A(H7N9) Virus through National Influenza-like Illness Surveillance, China , 2013, Emerging infectious diseases.

[3]  Yufei Wang,et al.  Deaths Associated With Avian Influenza A(H7N9) Virus in China , 2013, Annals of Internal Medicine.

[4]  M. Peiris,et al.  Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance , 2013, The Lancet.

[5]  G. Gao,et al.  Live-animal markets and influenza A (H7N9) virus infection. , 2013, The New England journal of medicine.

[6]  Jian He,et al.  Clinical findings in 111 cases of influenza A (H7N9) virus infection. , 2013, The New England journal of medicine.

[7]  N. Wong,et al.  Exposure to avian influenza H7N9 in farms and wet markets , 2013, The Lancet.

[8]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[9]  Andrew G. Watts,et al.  Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity , 2013, Science.

[10]  M. Boeckh,et al.  Combination Therapy with Amantadine, Oseltamivir and Ribavirin for Influenza a Infection: Safety and Pharmacokinetics , 2013, Antiviral therapy.

[11]  W. De-Eknamkul,et al.  Recent progress and challenges in the discovery of new neuraminidase inhibitors , 2013, Expert opinion on therapeutic patents.

[12]  N. White,et al.  Pharmacokinetic Properties ofAnti‐Influenza Neuraminidase Inhibitors , 2013, Journal of clinical pharmacology.

[13]  L. Gubareva,et al.  Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors , 2013, Influenza and other respiratory viruses.

[14]  M. Ison.  Clinical use of approved influenza antivirals: therapy and prophylaxis , 2013, Influenza and other respiratory viruses.

[15]  J. McKimm-Breschkin,et al.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance , 2013, Influenza and other respiratory viruses.

[16]  C. Beck,et al.  Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic , 2013, Influenza and other respiratory viruses.

[17]  E. Govorkova.  Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir‐resistant influenza A viruses , 2013, Influenza and other respiratory viruses.

[18]  K. Reisinger,et al.  Safety and tolerability of a 6‐week course of oseltamivir prophylaxis for seasonal influenza in children , 2012, Influenza and other respiratory viruses.

[19]  R. Moss,et al.  A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. , 2012, The Journal of infectious diseases.

[20]  C. Leport,et al.  Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. , 2012, Antiviral research.

[21]  C. Beck,et al.  Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. , 2012, Journal of Infectious Diseases.

[22]  Fei Zhao,et al.  Recent Advances in Neuraminidase Inhibitor Development as Anti‐influenza Drugs , 2012, ChemMedChem.

[23]  C. Davis,et al.  Evolutionary History and Phylodynamics of Influenza A and B Neuraminidase (NA) Genes Inferred from Large-Scale Sequence Analyses , 2012, PloS one.

[24]  K. Das.  Antivirals targeting influenza A virus. , 2012, Journal of medicinal chemistry.

[25]  Caitlin E. Mullarkey,et al.  T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine , 2012, The Pediatric infectious disease journal.

[26]  A. Perelson,et al.  Combination antiviral therapy for influenza: predictions from modeling of human infections. , 2012, The Journal of infectious diseases.

[27]  Herman Tse,et al.  Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned? , 2012, Clinical Microbiology Reviews.

[28]  D. Smee,et al.  Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. , 2012, Antiviral research.

[29]  D. Smee,et al.  Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses , 2012, PloS one.

[30]  Nancy R. Zhang,et al.  Ultrasensitive detection of rare mutations using next-generation targeted resequencing , 2011, Nucleic acids research.

[31]  R. Webster,et al.  Drugs in Development for Influenza , 2010, Drugs.

[32]  A. Perelson,et al.  Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus , 2011, PloS one.

[33]  R. Webster,et al.  Fitness of neuraminidase inhibitor-resistant influenza A viruses. , 2011, Current opinion in virology.

[34]  Min Soo Han,et al.  Triple-Combination Antiviral Drug for Pandemic H1N1 Influenza Virus Infection in Critically Ill Patients on Mechanical Ventilation , 2011, Antimicrobial Agents and Chemotherapy.

[35]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[36]  R. Webster,et al.  Novel Genotyping and Quantitative Analysis of Neuraminidase Inhibitor Resistance-Associated Mutations in Influenza A Viruses by Single-Nucleotide Polymorphism Analysis , 2011, Antimicrobial Agents and Chemotherapy.

[37]  David W. Smith,et al.  Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[38]  K. Thorlund,et al.  Systematic review of influenza resistance to the neuraminidase inhibitors , 2011, BMC infectious diseases.

[39]  F. Agou,et al.  Neuraminidase of 2007–2008 Influenza A(H1N1) Viruses Shows Increased Affinity for Sialic Acids Due to the D344N Substitution , 2011, Antiviral therapy.

[40]  R. Webster,et al.  Competitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferrets. , 2011, Influenza and other respiratory viruses.

[41]  Timothy B. Stockwell,et al.  Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. , 2011, The Journal of infectious diseases.

[42]  P. Tappenden,et al.  Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. , 2011, The Journal of infection.

[43]  Guy Boivin,et al.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. , 2011, The Journal of infectious diseases.

[44]  C. Beauchemin,et al.  The I222V Neuraminidase Mutation Has a Compensatory Role in Replication of an Oseltamivir-Resistant Influenza Virus A/H3N2 E119V Mutant , 2010, Journal of Clinical Microbiology.

[45]  T. Tamura,et al.  Identification of Oseltamivir Resistance among Pandemic and Seasonal Influenza A (H1N1) Viruses by an His275Tyr Genotyping Assay Using the Cycling Probe Method , 2010, Journal of Clinical Microbiology.

[46]  F. Tubach,et al.  Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial , 2010, PLoS medicine.

[47]  Ha T. Nguyen,et al.  Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  C. Boucher,et al.  Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. , 2010, The New England journal of medicine.

[49]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[50]  Vasiliy P. Mishin,et al.  In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses , 2010, Antimicrobial Agents and Chemotherapy.

[51]  G. Boivin,et al.  Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. , 2010, The Journal of infectious diseases.

[52]  D. Smee,et al.  Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro , 2010, PloS one.

[53]  N. Kobayashi,et al.  Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[54]  Erin Burns,et al.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. , 2010, MMWR. Morbidity and mortality weekly report.

[55]  Yoshihiro Kawaoka,et al.  T-705 (favipiravir) activity against lethal H5N1 influenza A viruses , 2009, Proceedings of the National Academy of Sciences.

[56]  Guy Boivin,et al.  Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. , 2009, The New England journal of medicine.

[57]  D. Smee,et al.  Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice , 2009, Antimicrobial Agents and Chemotherapy.

[58]  J. Gong,et al.  Pharmacophore model of influenza neuraminidase inhibitors--a systematic review. , 2009, Die Pharmazie.

[59]  Stefan Gravenstein,et al.  Influenza estacional en adultos y niños—Diagnóstico, tratamiento, quimioprofilaxis y control de brotes institucionales: Guías de práctica clínica de la Sociedad de Enfermedades Infecciosas de Estados Unidos de América , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[61]  Lynnette Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[62]  D. Smee,et al.  T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections , 2009, Antiviral Research.

[63]  James M Williams.  2009 update in prevention, evaluation, and outpatient treatment of influenza. , 2009, Current medical research and opinion.

[64]  L. Gubareva,et al.  Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. , 2009, Antiviral research.

[65]  L. Gubareva,et al.  Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. , 2009, Journal of infection and public health.

[66]  M. Holodniy,et al.  Oseltamivir for treatment and prophylaxis of influenza infection. , 2009, Expert opinion on drug safety.

[67]  Takanori Tomozawa,et al.  CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity , 2008, Antimicrobial Agents and Chemotherapy.

[68]  A. C. Krueger,et al.  Synthesis of potent pyrrolidine influenza neuraminidase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[69]  M. Zambon,et al.  Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[70]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[71]  N. Cox,et al.  Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. , 2007, The Journal of infectious diseases.

[72]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[73]  Xiyan Xu,et al.  Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern , 2005, The Lancet.

[74]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[75]  Gary Adam Zeitlin,et al.  Avian Influenza , 2005, Current infectious disease reports.

[76]  F. Hayden,et al.  Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir , 2003, Antimicrobial Agents and Chemotherapy.

[77]  L. Gubareva,et al.  Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. , 2003, The New England journal of medicine.

[78]  R. Lamb,et al.  Influenza A Virus M2 Ion Channel Activity Is Essential for Efficient Replication in Tissue Culture , 2002, Journal of Virology.

[79]  R. Webster,et al.  Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. , 2002, Antiviral research.

[80]  Paul W Smith,et al.  Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. , 1998, Structure.

[81]  R. Sidwell,et al.  Influenza virus resistance to neuraminidase inhibitors. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[82]  W G Laver,et al.  Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.

[83]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[84]  S Cusack,et al.  The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. , 1992, The EMBO journal.

[85]  J. N. Varghese,et al.  Structure of the catalytic and antigenic sites in influenza virus neuraminidase , 1983, Nature.

[86]  J. N. Varghese,et al.  Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution , 1983, Nature.